Showing 441-450 of 5061 results for "".
- Apremilast Phase III Results Show Efficacy Over Time for Psoriasishttps://practicaldermatology.com/news/20130311-apremilast_phase_iii_results_show_efficacy_over_time_for_psoriasis/2459597/Results from a new Phase III study presented at the AAD Meeting in Miami demonstrate the efficacy of the oral molecule apremilast (Celgene) in psoriasis patients. The ESTEEM 1 study evaluated efficacy and safety in a range of patients, approximately one-third of which was systemic and/or phototherap
- Red Alert: Rosacea Awareness Month Highlights Social Impact and Warning Signs of Rosaceahttps://practicaldermatology.com/news/20130215-red_alert_rosacea_awareness_month_highlights_social_impact_and_warning_signs_of_rosacea/2459615/According to a new patient survey conducted by the NRS, most rosacea patients feel the negative social impact of their condition regardless of which rosacea subtype they may have. While 61 percent of those with only subtype 1 (erythematotelangiectatic) ro
- Jan Marini Skin Research Launches Regeneration Boosterhttps://practicaldermatology.com/news/20130110-jan_marini_skin_research_launches_regeneration_booster/2459643/Jan Marini Skin Research released its all-new Regeneration Booster. Cycloastragenol, TGF Beta-1, multiple beneficial growth factors, and four advanced anti-aging peptides are combined with coenzyme Q10 and additional antioxidants to reduce the a
- Court: Off-label Drug Promotion Is Protected Speechhttps://practicaldermatology.com/news/20121204-court_off-label_drug_promotion_is_protected_speech/2459665/The 2nd US Circuit Court of Appeals in New York voted 2-1 to overturn a pharmaceutical salesman's conviction for off-label drug marketing, citing violations against his free speech rights under the First Amendment. The ruling could threaten FDA rules that prevent the marketing of treatments for uses
- New Practice Offers Personalized Procedureshttps://practicaldermatology.com/news/20120926-new_practice_offers_personalized_procedures/2459730/Dermatologist Candace Thornton Spann, MD, FAAD, and plastic surgeon Marvin Spann, MD, established a joint practice, Couture Dermatology & Plastic Surgery. The practice, which opens October 1, will offer custom-tailored treatments for all et
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree
- Enrollments Complete for Two Phase 2 ALA-PDT AK Trialshttps://practicaldermatology.com/news/20120424-enrollments_complete_for_two_phase_2_ala-pdt_ak_trials/2459815/DUSA Pharmaceuticals (NASDAQ GM: DUSA) completed patient enrollment in its Phase 2 clinical trial studying the broad area application with 1-, 2-, and 3-hour drug incubation for the treatment of actinic keratoses (AKs) of the face or scalp
- Lasers May Treat Burn Scars of Military, Civilianshttps://practicaldermatology.com/news/20120420-lasers_may_treat_burn_scars_of_military_civilians/2459817/Fractional laser procedures may offer a treatment option for the estimated 1 million American who survive serious burn injuries each year, according to experts presenting at the ASLMS Annual Meeting in Kissimmee, FL. According to Jill Waibel, MD, credited with performing one of (or pe
- Kythera Initiates Phase 3 trials for Investigational Injectablehttps://practicaldermatology.com/news/20120320-kythera_initiates_phase_3_trials_for_investigational_injectable/2459841/Kythera Biopharmaceuticals has initiated two Phase 3 trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental fat. The Phase 3 trials, known as REFINE-1 and REFINE-2 (Randomized Doubl
- Nathalie Daste Named LEO Pharma’s New Executive Vice President of Global People and Corporate Affairshttps://practicaldermatology.com/news/nathalie-daste-named-leo-pharmas-new-executive-vice-president-of-global-people-and-corporate-affairs/2461964/Nathalie Daste is LEO Pharma’s new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023. In her new role, Ms. Daste will head LEO Pharma’s Global People function as well as Corporate Affa